Use of the tumor necrosis factor-blockers for Crohn's disease

Table 21 Infliximab for fistulizing Crohn's disease: Induction and maintenance (%)

Study	Week of assessment	Outcome	IFX (mg/kg)		PL	TG
			5	10
Present et al[75]	18	Response	681	561	26	42-30
		Closure	551	381	13	42-25
(ACCENT II)	54	Response	461		23	23
		Closure	361		19	17

¹Complete closure of draining fistulas; P value for each IFX group vs placebo group. For IFX 5 mg/kg, the TG for fistula closure ranged from 42% at 18 wk to 23% to 54 wk. Adapted from CADTH (’09). These differences are statistically significant. See Tables 3 and 4 of the CADTH report for P-values, number of participants and events. IFX: Infliximab; PL: Placebo; TG: Therapeutic gain.